Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity.

Effects of antirheumatic agents on cytokines.

A review of the literature concerning the effects of traditional antirheumatic drugs on cytokines and the cytokine and anticytokine approaches already used in the therapy of rheumatoid arthritis (RA) is presented. Many antirheumatic drugs are capable of cytokine modulation in vitro. Corticosteroids inhibit the transcription of a broad spectrum of genes including those encoding monocyte, T cell-...

CIRCULATING SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS, INTERLEUKIN-2 RECEPTORS, TUMOR NECROSIS FACTOR a, AND INTERLEUKIN-6 LEVELS IN RHEUMATOID ARTHRITIS Longitudinal Evaluation During Methotrexate and Azathioprine Therapy

Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis.

In a recent study from our group, the combination of methotrexate and sulphasalazine (MTX + SASP) seemed superior to MTX alone in the treatment of rheumatoid arthritis (RA). To assess the impact of these therapies on the cytokine cascade, the in vitro production and circulating concentrations of several cytokines and endogenous cytokine antagonists were measured in 30 healthy controls and longi...

Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future.

Drug use during pregnancy is sometimes unavoidable, especially in chronic inflammatory diseases such as rheumatoid arthritis (RA). The use of disease-modifying antirheumatic drugs (DMARDs) often starts in the early stage of RA; therefore, women of reproductive age are at risk for exposure to a DMARD at time of conception as well as during pregnancy. The aim of this paper was to review recent li...

PReS-FINAL-2229: Pamidronate in CRMO - a small case series

Introduction Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory disorder which affects predominantly girls with peak onset between ages of 7 to 12 years. There is a frequent association of CRMO with inflammatory skin or gut disorders. Patients with isolated CRMO are usually treated with nonsteroidal antiinflammatory drugs (NSAIDs) prior to escalation to corticoids and ...